UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 16, 2008
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| | |
| 000-23265 | | 94-3267443 |
| (Commission File Number) | | (IRS Employer ID Number) |
| | |
| 1700 Perimeter Park Drive, Morrisville, North Carolina 27560 |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On May 16, 2008, Salix Pharmaceuticals, Ltd. issued a press release announcing that the U.S. Food and Drug Administration has issued an approvable letter for balsalazide tablet. A copy of this press release is attached as Exhibit 99.1.
On May 20, 2008, the company issued a press release announcing that the company presented at Digestive Disease Week 2008 new rifaximin Phase IIb data demonstrating significant and sustained improvement in diarrhea–associated irritable bowel syndrome. A copy of this press release is attached as Exhibit 99.2.
On May 20, 2008, the company issued a press release announcing that the company presented at Digestive Disease Week 2008 data from patients with mild-to-moderate ulcerative colitis taking 3.3 g balazide disodium demonstrating significantly greater quality of life improvements in bowel function, as well as improvement in their emotional state. A copy of this press release is attached as Exhibit 99.3.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| | |
Exhibit No. | | Description |
| 99.1 | | Press release dated May 16, 2008. |
| |
| 99.2 | | Press release dated May 20, 2008. |
| |
| 99.3 | | Press release dated May 20, 2008. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| | |
| | SALIX PHARMACEUTICALS, LTD. |
| Date: May 20, 2008 | | |
| |
| | /s/ Adam C. Derbyshire |
| | Adam C. Derbyshire |
| | Senior Vice President and Chief Financial Officer |
